Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Open, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a Pediatric Presentation (0.25 ml) of the Virosomal Hepatitis A Virus (HAV) Vaccine HAVpur in Healthy Young Children Aged Between and Including 18 Months to 47 Months, Using a 0/6 Month Immunization Schedule

NCT01349829 is registered in ClinicalTrials.gov with Crucell Holland BV as lead sponsor.

NCT NCT01349829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01349829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Open, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a Pediatric Presentation (0.25 ml) of the Virosomal Hepatitis A Virus (HAV) Vaccine HAVpur in Healthy Young Children Aged Between and Including 18 Months to 47 Months, Using a 0/6 Month Immunization Schedule
Lead sponsor
Crucell Holland BV
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2010
Completion date
April 30, 2011
Enrollment
251 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis a